Bausch Health Companies Inc.
BHCNext catalyst
Plecanatide
Chronic Idiopathic Constipation
Get an email about BHC's next catalysts
Track Bausch Health Companies (BHC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
plecanatide Phase 2 Est. Readout (Trulance)
Estimated primary completion for plecanatide trial (NCT07723924) in Functional Constipation (FC). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Bausch Health Companies Inc. (formerly Valeant and ICN Pharmaceuticals) is a global, diversified Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic pharmaceuticals, and over-the-counter products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America.
WebsiteFluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Hyperemia
Sirdalud
Vertebrogenic Radiculopathy L5, S1
Viramidine
Chronic Hepatitis C
IDP 121 Lotion
Acne
Encapsulated Mesalamine Granules (eMG)
Ulcerative Colitis
MOA-728
Constipation
Granulated mesalamine
Ulcerative Colitis
brodalumab
Psoriatic Arthritis
tramadol ER
Chronic Pain
Methylnaltrexone
Constipation
Tramadol HCl ER
Chronic Pain
SC Methylnaltrexone
Terminal Illness
Vitrase
Vitreous Hemorrhage
Budesonide MMX
Ulcerative Colitis
N-methylnaltrexone bromide (MOA-728)
Constipation
Loteprednol Etabonate
Inflammation
NOV03
Dry Eye Disease
bromfenac ophthalmic solution
Cataract Surgery
Ecabet
Dry Eye Syndromes
Fluocinolone acetonide
Noninfectious Posterior Uveitis
Besifloxacin
Bacterial Conjunctivitis
fluocinolone acetonide intravitreal implant
Noninfectious Posterior Uveitis
Loteprednol Etabonate Gel (BID)
Inflammation
double-blind rifaximin
Irritable Bowel Syndrome With Diarrhea
Sodium Fluorescein
Hyperemia
T-Pred
Cataract
Bromfenac
Allergic Conjunctivitis
BOL-303259-X
Open-Angle Glaucoma
Bepreve
Allergic Conjunctivitis
Voltaren
Vertebrogenic Radiculopathy L5, S1
Larsucosterol
Hepatitis
Infergen (Interferon Alfacon-1, CIFN) + Ribavirin (, based on body weight) for up to 48 wks
Chronic Hepatitis C
Bisacodyl
Chronic Idiopathic Constipation
IDP-121 Lotion
Acne
open-label rifaximin
Irritable Bowel Syndrome With Diarrhea
Plecanatide
Chronic Idiopathic Constipation
5 ASA, enemas, suppositories, corticosteroids
Ulcerative Colitis
ACYC
Acne
Retigabine
Postherpetic Neuralgia
IDP-126 Gel
Acne Vulgaris
IDP-118 Lotion
Plaque Psoriasis
IDP-124 Lotion
Atopic Dermatitis
Rifaximin (Xifaxan)
Clostridium Infections
Rifaximin
Irritable Bowel Syndrome
Rifaximin SSD
Hepatic Encephalopathy
Omeprazole sodium bicarbonate immediate release PWD/FS
Upper Gastrointestinal Bleeding
crofelemer
Irritable Bowel Syndrome
IDP-123 Lotion
Acne Vulgaris
Balsalazide disodium
Inflammatory Bowel Disease
IDP-122 Lotion
Plaque Psoriasis
IDP-120 Gel
Acne Vulgaris
Neuromultivit
Vertebrogenic Radiculopathy L5, S1
SP-333
Constipation
ISV-403
Bacterial Conjunctivitis
70 mg SC
Psoriasis
Pred Forte
Cataract
IV Methylnaltrexone (MNTX)
Postoperative Ileus
SC MNTX
Bowel Dysfunction
pradefovir mesylate
Hepatitis B, Chronic
Low Dose Rifaximin ER
Sickle Cell Disease
Low Dose MT-1303
Ulcerative Colitis
adefovir dipivoxyl
Hepatitis B, Chronic
loteprednol etabonate ophthalmic
Dry Eye
Rifaximin SSD IR
Liver Cirrhosis
IV Methylnaltrexone
Healthy Volunteers
IDP 120 Component A Gel
Acne Vulgaris
IDP-118 Monad HP Lotion
Plaque Psoriasis
JNJ 10229570-AAA
Acne Vulgaris
SAN-300
Rheumatoid Arthritis
Retin-A Micro facial acne treatment
Acne Vulgaris
Taribavirin
Chronic Hepatitis C
Low Dose Rifaximin DER
Sickle Cell Disease
Mesalamine Granules
Irritable Bowel Syndrome With Diarrhea
Tazorac Cream
Psoriasis
SP-304
Chronic Idiopathic Constipation
High Dose Rifaximin ER
Sickle Cell Disease
IDP-126 Component A
Acne Vulgaris
High Dose Rifaximin DER
Sickle Cell Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Phase 3 | Hyperemia | - | - |
Sirdalud | Phase 3 | Vertebrogenic Radiculopathy L5, S1 | - | - |
Viramidine | Phase 3 | Chronic Hepatitis C | - | - |
IDP 121 Lotion | Phase 3 | Acne | - | - |
Encapsulated Mesalamine Granules (eMG) | Phase 3 | Ulcerative Colitis | - | - |
MOA-728 | Phase 3 | Constipation | - | - |
Granulated mesalamine | Phase 3 | Ulcerative Colitis | - | - |
brodalumab | Phase 3 | Psoriatic Arthritis | - | - |
tramadol ER | Phase 3 | Chronic Pain | - | - |
Methylnaltrexone | Phase 3 | Constipation | - | - |
Tramadol HCl ER | Phase 3 | Chronic Pain | - | - |
SC Methylnaltrexone | Phase 3 | Terminal Illness | - | - |
Vitrase | Phase 3 | Vitreous Hemorrhage | - | - |
Budesonide MMX | Phase 3 | Ulcerative Colitis | - | - |
N-methylnaltrexone bromide (MOA-728) | Phase 3 | Constipation | - | - |
Loteprednol Etabonate | Phase 3 | Inflammation | - | - |
NOV03 | Phase 3 | Dry Eye Disease | - | - |
bromfenac ophthalmic solution | Phase 3 | Cataract Surgery | - | - |
Ecabet | Phase 3 | Dry Eye Syndromes | - | - |
Fluocinolone acetonide | Phase 3 | Noninfectious Posterior Uveitis | - | - |
Besifloxacin | Phase 3 | Bacterial Conjunctivitis | - | - |
fluocinolone acetonide intravitreal implant | Phase 3 | Noninfectious Posterior Uveitis | - | - |
Loteprednol Etabonate Gel (BID) | Phase 3 | Inflammation | - | - |
double-blind rifaximin | Phase 3 | Irritable Bowel Syndrome With Diarrhea | - | - |
Sodium Fluorescein | Phase 3 | Hyperemia | - | - |
T-Pred | Phase 3 | Cataract | - | - |
Bromfenac | Phase 3 | Allergic Conjunctivitis | - | - |
BOL-303259-X | Phase 3 | Open-Angle Glaucoma | - | - |
Bepreve | Phase 3 | Allergic Conjunctivitis | - | - |
Voltaren | Phase 3 | Vertebrogenic Radiculopathy L5, S1 | - | - |
Larsucosterol | Phase 3 | Hepatitis | - | - |
Infergen (Interferon Alfacon-1, CIFN) + Ribavirin (, based on body weight) for up to 48 wks | Phase 3 | Chronic Hepatitis C | - | - |
Bisacodyl | Phase 3 | Chronic Idiopathic Constipation | - | - |
IDP-121 Lotion | Phase 3 | Acne | - | - |
open-label rifaximin | Phase 3 | Irritable Bowel Syndrome With Diarrhea | - | - |
Plecanatide | Phase 3 | Chronic Idiopathic Constipation | - | - |
5 ASA, enemas, suppositories, corticosteroids | Phase 3 | Ulcerative Colitis | - | - |
ACYC | Phase 3 | Acne | - | - |
Retigabine | Phase 3 | Postherpetic Neuralgia | - | - |
IDP-126 Gel | Phase 3 | Acne Vulgaris | - | - |
IDP-118 Lotion | Phase 3 | Plaque Psoriasis | - | - |
IDP-124 Lotion | Phase 3 | Atopic Dermatitis | - | - |
Rifaximin (Xifaxan) | Phase 3 | Clostridium Infections | - | - |
Rifaximin | Phase 3 | Irritable Bowel Syndrome | - | - |
Rifaximin SSD | Phase 3 | Hepatic Encephalopathy | - | - |
Omeprazole sodium bicarbonate immediate release PWD/FS | Phase 3 | Upper Gastrointestinal Bleeding | - | - |
crofelemer | Phase 3 | Irritable Bowel Syndrome | - | - |
IDP-123 Lotion | Phase 3 | Acne Vulgaris | - | - |
Balsalazide disodium | Phase 3 | Inflammatory Bowel Disease | - | - |
IDP-122 Lotion | Phase 3 | Plaque Psoriasis | - | - |
IDP-120 Gel | Phase 3 | Acne Vulgaris | - | - |
Neuromultivit | Phase 3 | Vertebrogenic Radiculopathy L5, S1 | - | - |
SP-333 | Phase 2 | Constipation | - | - |
ISV-403 | Phase 2 | Bacterial Conjunctivitis | - | - |
70 mg SC | Phase 2 | Psoriasis | - | - |
Pred Forte | Phase 2 | Cataract | - | - |
IV Methylnaltrexone (MNTX) | Phase 2 | Postoperative Ileus | - | - |
SC MNTX | Phase 2 | Bowel Dysfunction | - | - |
pradefovir mesylate | Phase 2 | Hepatitis B, Chronic | - | - |
Low Dose Rifaximin ER | Phase 2 | Sickle Cell Disease | - | - |
Low Dose MT-1303 | Phase 2 | Ulcerative Colitis | - | - |
adefovir dipivoxyl | Phase 2 | Hepatitis B, Chronic | - | - |
loteprednol etabonate ophthalmic | Phase 2 | Dry Eye | - | - |
Rifaximin SSD IR | Phase 2 | Liver Cirrhosis | - | - |
IV Methylnaltrexone | Phase 2 | Healthy Volunteers | - | - |
IDP 120 Component A Gel | Phase 2 | Acne Vulgaris | - | - |
IDP-118 Monad HP Lotion | Phase 2 | Plaque Psoriasis | - | - |
JNJ 10229570-AAA | Phase 2 | Acne Vulgaris | - | - |
SAN-300 | Phase 2 | Rheumatoid Arthritis | - | - |
Retin-A Micro facial acne treatment | Phase 2 | Acne Vulgaris | - | - |
Taribavirin | Phase 2 | Chronic Hepatitis C | - | - |
Low Dose Rifaximin DER | Phase 2 | Sickle Cell Disease | - | - |
Mesalamine Granules | Phase 2 | Irritable Bowel Syndrome With Diarrhea | - | - |
Tazorac Cream | Phase 2 | Psoriasis | - | - |
SP-304 | Phase 2 | Chronic Idiopathic Constipation | - | - |
High Dose Rifaximin ER | Phase 2 | Sickle Cell Disease | - | - |
IDP-126 Component A | Phase 2 | Acne Vulgaris | - | - |
High Dose Rifaximin DER | Phase 2 | Sickle Cell Disease | - | - |
Frequently asked questions
What is in Bausch Health Companies Inc.'s drug pipeline?→
CatalystAlert tracks 78 drug candidates in Bausch Health Companies Inc.'s (BHC) pipeline across Phase 3, Phase 2. Its lead program is Plecanatide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bausch Health Companies Inc.'s next FDA catalyst?→
Bausch Health Companies Inc.'s (BHC) next tracked catalyst is a Phase 2 readout expected Q4 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BHC biotech catalysts?→
Add BHC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bausch Health Companies Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.